Migliorati Cesar A, Brennan Michael T, Peterson Douglas E
Department of Oral and Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL.
Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC.
J Natl Cancer Inst Monogr. 2019 Aug 1;2019(53). doi: 10.1093/jncimonographs/lgz009.
Medication-related osteonecrosis of the jaw is an oral complication in cancer patients being treated with either antiresorptive or antiangiogenic drugs. The first reports of MRONJ were published in 2003. Hundreds of manuscripts have been published in the medical and dental literature describing the complication, clinical and radiographic signs and symptoms, possible pathophysiology, and management. Despite this extensive literature, the pathobiological mechanisms by which medication-related osteonecrosis of the jaw develops have not yet been fully delineated. The aim of this manuscript is to present current knowledge about the complication ragarding to the definition, known risk factors, and clinical management recommendations. Based on this current state of the science, we also propose research directions that have potential to enhance the management of future oncology patients who are receiving these agents.
药物相关性颌骨坏死是接受抗吸收或抗血管生成药物治疗的癌症患者的一种口腔并发症。关于药物相关性颌骨坏死的首批报告于2003年发表。医学和牙科文献中已发表了数百篇描述该并发症、临床和影像学体征及症状、可能的病理生理学和治疗方法的手稿。尽管有大量此类文献,但药物相关性颌骨坏死发生的病理生物学机制尚未完全阐明。本手稿的目的是介绍有关该并发症在定义、已知危险因素和临床管理建议方面的当前知识。基于目前的科学状况,我们还提出了一些研究方向,这些方向有可能改善未来接受这些药物治疗的肿瘤患者的管理。